Table 1.
Patient demographics and clinical characteristics at baseline.
| All patients | Non-SCS | Q1 | Q2 | Q3 | Q4 | |
|---|---|---|---|---|---|---|
| N = 10,579 | N = 7476 | N = 749 | N = 802 | N = 775 | N = 777 | |
| Age | ||||||
| Mean (SD), years | 48.0 (12.2) | 48.0 (12.3) | 46.7 (12.0) | 47.6 (11.9) | 47.8 (12.1) | 50.3 (12.0) |
| Sex | ||||||
| Male, n (%) | 5277 (49.9) | 3955 (52.9) | 328 (43.8) | 330 (41.1) | 316 (40.8) | 348 (44.8) |
| Female, n (%) | 5302 (50.1) | 3521 (47.1) | 421 (56.2) | 472 (58.9) | 459 (59.2) | 429 (55.2) |
| Asthma severity and control status | ||||||
| Severe asthma | 823 (7.8) | 274 (3.7) | 33 (4.4) | 70 (8.7) | 91 (11.7) | 355 (45.7) |
| Uncontrolled, n (%) | 267 (2.5) | 33 (0.4) | 11 (1.5) | 13 (1.6) | 33 (4.3) | 177 (22.8) |
| Controlled, n (%) | 556 (5.3) | 241 (3.2) | 22 (2.9) | 57 (7.1) | 58 (7.5) | 178 (22.9) |
| Mild-to-moderate asthma | 9756 (92.2) | 7202 (96.3) | 716 (95.6) | 732 (91.3) | 684 (88.3) | 422 (54.3) |
| Uncontrolled, n (%) | 1646 (15.6) | 637 (8.5) | 210 (28.0) | 224 (27.9) | 293 (37.8) | 282 (36.3) |
| Controlled, n (%) | 8110 (76.7) | 6565 (87.8) | 506 (67.6) | 508 (63.3) | 391 (50.5) | 140 (18.0) |
| Daily SCS dosage during 12 months before the index date | ||||||
| Mean (SD), mg/day | 0.42 (1.69) | 0 (0) | 0.08 (0.04) | 0.29 (0.08) | 0.79 (0.25) | 4.58 (4.42) |
| Total number of days on which SCS were administered during 12 months before the index datea | ||||||
| Mean (SD), days | 12.54 (52.71) | 0 (0) | 3.96 (4.97) | 8.27 (11.90) | 24.86 (47.13) | 133.60 (138.05) |
SD standard deviation, SCS systemic corticosteroid, Q quartile.
aExcluding intermittent use of SCS.